Provectus announced that the company has entered into an option agreement with the University of Miami (UM) for an exclusive worldwide license of intellectual property developed by the Ophthalmic Biophysics Center (OBC) of Bascom Palmer Eye Institute (BPEI), which is part of the UM Health System, for the use of OBC's photodynamic antimicrobial therapy (PDAT) medical device in combination with Provectus' proprietary pharmaceutical-grade rose bengal for the treatment of bacterial, fungal, and viral infections of the eye. The Company also initiated a sponsored research program with OBC to investigate Provectus' rose bengal for the treatment of infectious keratitis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1484 USD | +0.94% | -6.08% | +54.58% |
1st Jan change | Capi. | |
---|---|---|
+54.58% | 61.67M | |
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- PVCT Stock
- News Provectus Biopharmaceuticals, Inc.
- Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections